{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T21:55:17Z","timestamp":1765230917596},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,10,8]],"date-time":"2009-10-08T00:00:00Z","timestamp":1254960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Infection with influenza A (H1N1)<jats:italic>v<\/jats:italic> (swine flu) has caused widespread anxiety, among patients who are potentially immunocompromised, such as those being treated for inflammatory bowel disease.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold> To provide guidance for physicians and their patients on the risk, prevention and management of influenza A (H1N1)<jats:italic>v<\/jats:italic> infection.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> Medline was searched using the following key words: \u2018swine flu\u2019, \u2018immunosuppression\u2019, inflammatory bowel disease\u2019, \u2018recommendations\u2019, \u2018immunization\u2019, \u2018vaccination\u2019. Organizations such as European Centre for Disease Prevention and Control, the Centers for Disease Control and Prevention and the World Health Organization were consulted for recent papers and recommendations regarding immunocompromised patients and influenza A (H1N1)<jats:italic>v<\/jats:italic> infection.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Pandemic influenza A (H1N1) virus predominantly affects young patients. Those who are immunocompromised because of underlying disease or treatment are considered at higher risk of complications from influenza A (H1N1). They should be offered prevention (vaccination, postexposure prophylaxis) or treatment with antiviral drugs, if affected. Pneumococcal infection is a complication of influenza infection; therefore, pneumococcal vaccination appears advisable. Seasonal influenza vaccination is also recommended. Withdrawal of immunosuppressive treatment appears advisable during severe active infection if possible.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Pragmatic advice is the best that can be offered in the current circumstances because of paucity of evidence. Investigation into the impact of influenza A (H1N1)<jats:italic>v<\/jats:italic> infection in young people with chronic conditions is needed.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2009.04161.x","type":"journal-article","created":{"date-parts":[[2009,10,8]],"date-time":"2009-10-08T05:22:30Z","timestamp":1254979350000},"page":"5-10","source":"Crossref","is-referenced-by-count":19,"title":["Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease"],"prefix":"10.1111","volume":"31","author":[{"given":"J.\u2010F.","family":"RAHIER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"YAZDANPANAH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"VIGET","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"TRAVIS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010F.","family":"COLOMBEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,12,2]]},"reference":[{"key":"e_1_2_8_2_2","first-page":"400","article-title":"Swine influenza A (H1N1) infection in two children \u2013 Southern California, March\u2010April 2009","volume":"58","author":"Ginsberg M","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.2807\/ese.14.33.19309-en"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1176062"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1206.051141"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-05"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0903810"},{"issue":"34","key":"e_1_2_8_8_2","doi-asserted-by":"crossref","DOI":"10.2807\/ese.14.34.19319-en","article-title":"Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009","volume":"14","author":"Baker MG","year":"2009","journal-title":"Euro Surveill"},{"key":"e_1_2_8_9_2","unstructured":"European Center for Disease Prevention and Control (ECDC).Personal protective measures for reducing the risk of acquiring or transmitting human influenza. May 2009. Available at:http:\/\/ecdc.europa.eu\/en\/healthtopics\/Pages\/Influenza_A(H1N1)_Personal_Protective_Measures.aspx."},{"key":"e_1_2_8_10_2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0907650","article-title":"Trial of Influenza A (H1N1) 2009 Monovalent MF59\u2010Adjuvanted Vaccine \u2010\u2010 Preliminary Report","author":"Clark TW","year":"2009","journal-title":"New Engl J Med"},{"key":"e_1_2_8_11_2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa0907413","article-title":"Response after One Dose of a Monovalent Influenza A (H1N1) 2009 Vaccine \u2010\u2010 Preliminary Report","author":"Greenberg ME","year":"2009","journal-title":"New Engl J Med"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2007.02.035"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.120"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282ffdeca"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.002"},{"key":"e_1_2_8_16_2","unstructured":"European Center for Disease Prevention and Control (ECDC).Use of specific pandemic influenza vaccines during H1N1 2009 pandemic. August 2009. Available at:http:\/\/ecdc.europa.eu\/en\/healthtopics\/Documents\/0908_Influenza_AH1N1_On_the_use_of_specific_pandemic_influenza_vaccines.pdf."},{"key":"e_1_2_8_17_2","first-page":"1","article-title":"Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"58","author":"Morse D","year":"2009","journal-title":"MMWR Recomm Rep"},{"issue":"31","key":"e_1_2_8_18_2","doi-asserted-by":"crossref","DOI":"10.2807\/ese.14.31.19288-en","article-title":"Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveillance trends, age of infection and effectiveness of seasonal vaccination","volume":"14","author":"Kelly H","year":"2009","journal-title":"Euro Surveill"},{"key":"e_1_2_8_19_2","first-page":"47","article-title":"European evidence\u2010based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier JF","year":"2009","journal-title":"JCC"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2008.175950"},{"key":"e_1_2_8_21_2","unstructured":"European Center for Disease Prevention and Control (ECDC).Public health use of influenza antivirals during influenza pandemics. August 2009. Available at:http:\/\/ecdc.europa.eu\/en\/publications\/Publications\/0907_GUI_Public_Health_use_of_Influenza_Antivirals_during_Influenza_Pandemic.pdf."},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050740"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.8.1016"},{"key":"e_1_2_8_24_2","unstructured":"World Health Organization.WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. August 2009. Available at:http:\/\/www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_use_antivirals_20090820\/en\/index.html."},{"key":"e_1_2_8_25_2","first-page":"893","article-title":"Oseltamivir\u2010resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients \u2010 Seattle, Washington","volume":"58","author":"Englund J","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"e_1_2_8_26_2","unstructured":"Use of Oseltamivir in Patients Taking Methotrexate. June 2009. Available at:http:\/\/www.nelm.nhs.uk\/en\/Original\u2010search\/?query=tamiflu%2520methotrexate."}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2009.04161.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2009.04161.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T20:08:03Z","timestamp":1698782883000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2009.04161.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,2]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1365-2036.2009.04161.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2009.04161.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,2]]}}}